Last Updated: August 8, 2026
Philips Respironics fully funded its personal injury settlement on March 14, 2025, in litigation centralized as MDL 3014 in the U.S. District Court for the Western District of Pennsylvania. The resolution combines a $1.075 billion private personal injury program, a $25 million medical-monitoring fund, and a separate economic-loss class action, illustrating key mass tort distinctions.
The official settlement record provides no start or completion date for individual payments. This article examines the factual record, MDL proceedings, settlement amounts, claims administration, continuing litigation, and legal principles affecting practitioners.
Settlement Program Timeline
The settlement materials and MDL docket establish the program's principal milestones. The matter is a medical device settlement involving a $1.075 billion personal injury resolution.
Every major settlement window has now closed. No official individual payment schedule has been published, and the remaining options depend on the claimant's settlement track and registration status.
- Registered personal injury claimants request status information through the personal injury administrator.
- Economic-loss class members check status through respironicscpap-elsettlement.com.
- Anyone with device-related health problems can use the FDA's health reporting portal, though reporting does not extend limitations periods.
- Claimants who missed the deadlines should consult a licensed attorney about an individual filing and applicable state statutes of limitations.
Recall Defects and FDA Findings
The lawsuits concern polyester-based polyurethane (PE-PUR) sound-abatement foam that can release black particles and degradation products. The FDA identified those products as toluene diisocyanate isomers, toluene diamine isomers, and diethylene glycol. The regulatory record addresses both potential exposure and Philips' response to the foam problem.
The FDA classified the June 14, 2021 recall as Class I. Its recalled-device page and FDA recall record cover roughly 15 million devices worldwide. More than 116,000 medical device reports, including 561 reports of death, were received from April 2021 through September 30, 2023, though MDRs alone cannot establish incidence or causation.
The notice question predates the recall by roughly six years. In its Section 518(b) proposal, CDRH recorded that Philips issued internal documentation in November 2015 addressing the foam maintenance procedure, that this was the company's only documentation on the issue, and that Philips representatives confirmed no further investigation, health hazard evaluation, risk analysis, or design review was performed or documented at that time. The recall followed in June 2021.
A federal court entered a consent decree of permanent injunction on April 9, 2024, restricting production and sale of new CPAP and BiPAP devices at several U.S. facilities until specified requirements are met.
The U.S. patient portal closed January 1, 2026, and repaired and replacement devices use silicone foam. The FDA recommends continuing to use a repaired or replaced device while independent testing proceeds, because stopping may be more harmful, and advises against adding filters. Patients should consult their clinicians before changing therapy.
MDL 3014 Claim Categories
In re: Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability Litigation, No. 2:21-mc-01230 (W.D. Pa. 2021), was consolidated before Judge Joy Flowers Conti by a transfer order filed October 8, 2021, following the Panel's September 30, 2021 hearing session. The proceeding encompasses economic-loss, personal injury, and medical-monitoring tracks, and the legal structure and available relief differ materially among them.
Substantive eligibility may extend across economic-loss award types, but it does not reopen an expired filing deadline. Receiving 100% of a Device Replacement Claim Amount may preclude a Device Return Award under the settlement terms. The personal injury program is a private, non-class agreement.
The court's approval opinion describes a Settlement Fund of not less than $495 million, a $506.3 million non-reversionary prefund, and a $613.3 million minimum constructive common fund.
Settlement Structure and Approval
The economic-loss class received final approval on April 25, 2024, and medical monitoring received final judgment on December 5, 2024. The private personal injury program was governed by the Master Settlement Agreement rather than by either class settlement.
Court approval applied only to the two class tracks, although related personal injury filings and administrative orders remain on the MDL docket. BrownGreer PLC serves as personal injury administrator, settlement administrator, and qualified settlement fund fiduciary, with Matt Garretson appointed Allocation Special Master. The MSA bars payment until a claimant completes a valid, signed release.
Litigation Strategy and MDL Leadership
In complex MDLs, Science Day coordination with the SoClean MDL included court-supervised presentations on device materials, related issues, medical literature, and regulatory information. Philips' operative amended third-party contribution complaint against SoClean was dismissed without prejudice, with permission to file a second amended complaint.
Payouts and Claims Administration
No official per-claimant award or payment date is public. The SEC-filed MSA states that "there is no assurance at this time as to the precise amount of such payment." Individual offers use a non-public methodology administered by BrownGreer and the Allocation Special Master, and the Extraordinary Injury Fund reviewed exceptional claims through August 1, 2025.
Qualifying conditions include specified respiratory injuries and cancers. The broader respiratory category includes asthma, COPD, chronic bronchitis, bronchiectasis, pulmonary fibrosis, sarcoidosis, acute respiratory distress syndrome, reactive airways dysfunction syndrome, pneumonitis, other interstitial lung disease, and other obstructive or restrictive lung disease. Covered cancers include lung cancer, certain blood cancers, and specified ENT or airway cancers.
On the economic-loss side, device payment awards range from $55.63 for a DreamStation CPAP to $1,552.25 for Trilogy-family ventilators, plus a $100 device-return award.
Deadlines and Post-Deadline Compliance
The court confirmed that personal injury participation deadlines expired. Late registration is possible only if the parties jointly waive the deadline case by case, though a new individual lawsuit may remain available. Participation required proof of recalled-device use and serial-number verification, medical documentation of a qualifying injury, and proof of U.S. citizenship or residency.
Under the Docket Management Order, post-deadline filers become Litigating Plaintiffs subject to strict requirements. Noncompliance can bring dismissal with prejudice, as five cases dismissed on October 3, 2025 illustrate. Lien resolution also precedes disbursement.
Objections and Attorney Fees
Because fairness review reached only the class tracks, none of what follows governs the private program. Objections addressed frustration with Philips, concerns about being forced into a settlement or enrolled in the MAP Registry, responsibility for attorneys' fees, the size of the fund, and preservation of individual claims under the medical-monitoring final judgment.
Fee awards divide by track. The economic-loss award at ECF No. 2737 totaled $94,440,614.59 in fees and $559,385.41 in costs, and the medical-monitoring award at ECF No. 3054 totaled $4,369,754.57 in fees and $451,245.43 in costs. Personal injury compensation runs through private retainers and a common-benefit fund.
Counsel must therefore distinguish class membership from private personal injury registration, and identify the relevant track before comparing deadlines, fees, releases, or awards.
Future Legal Developments
Philips' FY2025 Annual Report states Respironics cannot sell new U.S. respiratory-care devices until it meets consent-decree requirements, and the FDA has not issued written notice of compliance. Charges included EUR 20 million in Q1 and EUR 50 million in Respironics-related charges in Q2. A September 2025 FDA warning letter followed inspections at three facilities.
An April 21, 2026 scheduling order set general-causation expert work through July 30 and evidentiary briefing from August 27 through October 15, 2026. It also stayed proceedings for noncompliant plaintiffs pending further court order, and no trial date has been set. Philips disclosed active engagement with U.S. and Australian authorities.
Practice Implications for Pending Claims
Plaintiff counsel must separate settlement-track eligibility from any remaining individual claim, document recalled-device use and qualifying diagnoses, evaluate release scope, and resolve liens before projecting disbursement timing. Defense counsel must track deadline enforcement, causation evidence, release compliance, and the continuing expert schedule, because the funded resolution does not end all MDL exposure.
The absence of public award amounts limits reliable valuation comparisons, while dismissals for noncompliance make docket management a substantive risk. For additional context on mass-settlement payment timing, see the staged administration of the 3M earplug settlement.
